Aeterna Zentaris Inc. (NASDAQ:AEZS) has earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Brokerages have set a 12-month consensus target price of $11.00 for the company and are predicting that the company will post ($0.74) EPS for the current quarter, according to Zacks. Zacks has also given Aeterna Zentaris an industry rank of 107 out of 265 based on the ratings given to related companies.
A number of research analysts have commented on AEZS shares. Maxim Group restated a “buy” rating and set a $11.00 price objective on shares of Aeterna Zentaris in a research note on Tuesday, July 5th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Aeterna Zentaris in a research note on Sunday, July 10th. Zacks Investment Research raised Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, August 15th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $9.00 target price on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd.
A hedge fund recently raised its stake in Aeterna Zentaris stock. Renaissance Technologies LLC raised its position in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 at the end of the most recent reporting period. Institutional investors own 8.28% of the company’s stock.
Shares of Aeterna Zentaris (NASDAQ:AEZS) opened at 3.39 on Wednesday. The firm’s market capitalization is $33.69 million. Aeterna Zentaris has a 52-week low of $2.60 and a 52-week high of $15.70. The firm’s 50-day moving average price is $3.52 and its 200-day moving average price is $3.54.
Aeterna Zentaris (NASDAQ:AEZS) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative return on equity of 241.78% and a negative net margin of 5,871.45%. On average, equities analysts predict that Aeterna Zentaris will post ($2.61) earnings per share for the current fiscal year.
About Aeterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.